Harold J. Burstein, MD, PhD, on HR+ Early Breast Cancer: Update of the SOFT Trial

2017 San Antonio Breast Cancer Symposium
Tweet this page

Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, discusses study findings on a comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive breast cancer (Abstract GS4-03).

Advertisement

Advertisement



Advertisement